Cargando…
A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes
LY2881835 is a selective, potent, and efficacious GPR40 agonist. The objective of the studies described here was to examine the pharmacological properties of LY2881835 in preclinical models of T2D. Significant increases in insulin secretion were detected when LY2881835 was tested in primary islets f...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226292/ https://www.ncbi.nlm.nih.gov/pubmed/28097011 http://dx.doi.org/10.1002/prp2.278 |
_version_ | 1782493631769214976 |
---|---|
author | Chen, Yanyun Song, Min Riley, Jonathan P. Hu, Charlie C. Peng, Xianbu Scheuner, Donalyn Bokvist, Krister Maiti, Pranab Kahl, Steven D. Montrose‐Rafizadeh, Chahrzad Hamdouchi, Chafiq Miller, Anne Reifel |
author_facet | Chen, Yanyun Song, Min Riley, Jonathan P. Hu, Charlie C. Peng, Xianbu Scheuner, Donalyn Bokvist, Krister Maiti, Pranab Kahl, Steven D. Montrose‐Rafizadeh, Chahrzad Hamdouchi, Chafiq Miller, Anne Reifel |
author_sort | Chen, Yanyun |
collection | PubMed |
description | LY2881835 is a selective, potent, and efficacious GPR40 agonist. The objective of the studies described here was to examine the pharmacological properties of LY2881835 in preclinical models of T2D. Significant increases in insulin secretion were detected when LY2881835 was tested in primary islets from WT mice but not in islets from GPR40 KO mice. Furthermore, LY2881835 potentiated glucose stimulated insulin secretion in normal lean mice. Acute administration of LY2881835 lowered glucose during OGTTs in WT mice but not in GPR40 KO mice. These findings demonstrate that LY2881835 induces GPR40‐mediated activity ex vivo and in vivo. LY2881835 was administered orally at 10 mg/kg to diet‐induced obese (DIO) mice (an early model of T2D due to insulin resistance) for 14 days. Statistically significant reductions in glucose were seen during OGTTs performed on days 1 and 15. When a study was done for 3 weeks in Zucker fa/fa rats, a rat model of insulin resistance, normalization of blood glucose levels equivalent to those seen in lean rats was observed. A similar study was performed in streptozotocin (STZ)‐treated DIO mice to explore glucose control in a late model of T2D. In this model, pancreatic insulin content was reduced ~80% due to STZ‐treatment plus the mice were insulin resistant due to their high fat diet. Glucose AUCs were significantly reduced during OGTTs done on days 1, 7, and 14 compared to control mice. In conclusion, these results demonstrate that LY2881835 functions as a GPR40‐specific insulin secretagogue mediating immediate and durable glucose control in rodent models of early‐ and late‐stage T2D. |
format | Online Article Text |
id | pubmed-5226292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52262922017-01-17 A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes Chen, Yanyun Song, Min Riley, Jonathan P. Hu, Charlie C. Peng, Xianbu Scheuner, Donalyn Bokvist, Krister Maiti, Pranab Kahl, Steven D. Montrose‐Rafizadeh, Chahrzad Hamdouchi, Chafiq Miller, Anne Reifel Pharmacol Res Perspect Original Articles LY2881835 is a selective, potent, and efficacious GPR40 agonist. The objective of the studies described here was to examine the pharmacological properties of LY2881835 in preclinical models of T2D. Significant increases in insulin secretion were detected when LY2881835 was tested in primary islets from WT mice but not in islets from GPR40 KO mice. Furthermore, LY2881835 potentiated glucose stimulated insulin secretion in normal lean mice. Acute administration of LY2881835 lowered glucose during OGTTs in WT mice but not in GPR40 KO mice. These findings demonstrate that LY2881835 induces GPR40‐mediated activity ex vivo and in vivo. LY2881835 was administered orally at 10 mg/kg to diet‐induced obese (DIO) mice (an early model of T2D due to insulin resistance) for 14 days. Statistically significant reductions in glucose were seen during OGTTs performed on days 1 and 15. When a study was done for 3 weeks in Zucker fa/fa rats, a rat model of insulin resistance, normalization of blood glucose levels equivalent to those seen in lean rats was observed. A similar study was performed in streptozotocin (STZ)‐treated DIO mice to explore glucose control in a late model of T2D. In this model, pancreatic insulin content was reduced ~80% due to STZ‐treatment plus the mice were insulin resistant due to their high fat diet. Glucose AUCs were significantly reduced during OGTTs done on days 1, 7, and 14 compared to control mice. In conclusion, these results demonstrate that LY2881835 functions as a GPR40‐specific insulin secretagogue mediating immediate and durable glucose control in rodent models of early‐ and late‐stage T2D. John Wiley and Sons Inc. 2016-11-21 /pmc/articles/PMC5226292/ /pubmed/28097011 http://dx.doi.org/10.1002/prp2.278 Text en © 2016 Eli Lilly and Company. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Chen, Yanyun Song, Min Riley, Jonathan P. Hu, Charlie C. Peng, Xianbu Scheuner, Donalyn Bokvist, Krister Maiti, Pranab Kahl, Steven D. Montrose‐Rafizadeh, Chahrzad Hamdouchi, Chafiq Miller, Anne Reifel A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes |
title | A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes |
title_full | A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes |
title_fullStr | A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes |
title_full_unstemmed | A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes |
title_short | A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes |
title_sort | selective gpr40 (ffar1) agonist ly2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226292/ https://www.ncbi.nlm.nih.gov/pubmed/28097011 http://dx.doi.org/10.1002/prp2.278 |
work_keys_str_mv | AT chenyanyun aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT songmin aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT rileyjonathanp aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT hucharliec aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT pengxianbu aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT scheunerdonalyn aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT bokvistkrister aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT maitipranab aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT kahlstevend aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT montroserafizadehchahrzad aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT hamdouchichafiq aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT millerannereifel aselectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT chenyanyun selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT songmin selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT rileyjonathanp selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT hucharliec selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT pengxianbu selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT scheunerdonalyn selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT bokvistkrister selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT maitipranab selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT kahlstevend selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT montroserafizadehchahrzad selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT hamdouchichafiq selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes AT millerannereifel selectivegpr40ffar1agonistly2881835providesimmediateanddurableglucosecontrolinrodentmodelsoftype2diabetes |